Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

Why is DoorDash acquiring Deliveroo and SevenRooms? How will Trump's tariffs impact toy prices? What caused Newark Airport's recent flight chaos? Why did AMD report strong Q1 revenue growth? How are US-China trade talks evolving this week? What is behind WeightWatchers' recent bankruptcy filing? Why are Tesla’s European sales plummeting? How has Trump's trade policy affected US exports? What are the implications of EU-US tariff tensions?

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

benzinga.com/general/biotech/25/05/45208634/why-did-ptc-therapeutics-stock-fall-on-monday-despite-mid-stage-study-for-huntingtons-hits-primar

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients.
Huntington’s disease is a progressive neurodegenerative disorder caused by mutation of the huntingtin (HTT)…

This story appeared on benzinga.com, 2025-05-05 20:54:20.